MedTrace Logo

µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

NCT01153425 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-08-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology to evaluate the response to drug intervention involving two treatment arms of postmenopausal participants with osteoporosis, randomized into either a teriparatide (Forteo™) or zoledronic acid (Reclast™) group.

Conditions

  • Osteoporosis, Osteopenia

Interventions

OTHER

Virtual Bone Biopsy

MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.

DRUG

Teriparatide

Participants are clinically indicated for treatment.

DRUG

Zoledronic Acid

Participants are clinically indicated for treatment.

Sponsors & Collaborators

Principal Investigators

  • Felix W. Wehrli, Ph.D. · University of Pennsylvania, Department of Radiology

  • Peter J. Snyder, M.D. · University Of Pennsylvania, Department of Endocrinology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2012-12-31
Completion
2012-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153425 on ClinicalTrials.gov